Search results
Scientists reveal how an unstructured protein traps cancer-promoting molecules
Medical Xpress· 2 days agoThe findings shed light on how prostate cancer advances from treatable to aggressive,...
AstraZeneca's Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial -...
Benzinga· 3 days agoTuesday, AstraZeneca Plc AZN announced topline data from the CAPItello-290 Phase 3 trial for Truqap...
AstraZeneca's Advanced Breast Cancer Drug Fails to Meet Primary Goals
Morningstar· 4 days agoAstraZeneca said a late-stage study showed that its therapy for advanced or metastatic triple-negative breast cancer didn't meet its ...
What does malignant mean? And why it matters greatly when it comes to tumors and your health.
USA TODAY via Yahoo News· 5 days agoScott Eggener, a urologic oncologist and the co-director of the UChicago Medicine High-Risk and Advanced Prostate Cancer Clinic. How ...
Medicare must fund blood-based cancer screenings. NY's delegatin must act
Lohud | The Journal News via Yahoo News· 3 days agoDetection Screening Coverage Act, that would cut through this red tape and create a pathway to...
AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study
Zacks· 4 days agoAstraZeneca's (AZN) phase III CAPItello-290 study evaluating Truqap plus chemotherapy in patients with locally advanced/metastatic triple-negative breast cancer fails to meet the dual primary endpoints.
Father and son's powerful message after both diagnosed with incurable cancer
Daily Express· 6 days agoA father and son believe they have been “brought closer together” after they received the same...
AstraZeneca’s Truqap flops in Phase III triple negative breast cancer trial
Clinical Trials Arena via Yahoo Finance· 2 days agoWhile AstraZeneca originally hoped for approval for all ...III KEYNOTE-522 trial (NCT03036488) of...
Gateway - The Root
The Root· 4 days agoAccording to a new report from American Cancer Society, Black men and women are more likely to die from uterine, breast and prostate cancer< ...
Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs
BioPharma Dive via Yahoo Finance· 8 hours agoA medicine Jazz acquired in 2019 missed the goal of a Phase 2 study. Elsewhere, Vanda rejected two...